Best Biotech Podcasts (2026)

1
An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages 29:20

1h ago29:20

29:20

One of the challenges in treating the neurodegenerative condition Alzheimer’s disease is intervening early enough in the course of illness to provide meaningful benefit. AltPep is developing therapeutics with companion diagnostics that target toxic α-sheet–containing oligomers, which are thought to form very early in the disease and act as molecula…

1
Planning For Potential Pandemics: The Coalition for Epidemic Preparedness Innovations 22:28

1h ago22:28

22:28

As we all learned in 2020, getting ahead of the next major pandemic is a matter of global concern. For the Coalition for Epidemic Preparedness Innovations, or CEPI (cepi.net), it is their reason for existing. Joining me for this conversation are Valentina Bernasconi, Head of Laboratory Science for CEPI, and Marie-Eve Poupart, Lead Scientist In Char…

1
Best of: The future of motivation 31:28

6d ago31:28

31:28

We're here to wish you a very happy New Year! We hope you’re ringing in the new year in good health and looking forward to what’s ahead in 2026. As people are setting goals and making resolutions, we’re re-running an episode today on the future of motivation. Last year, we sat down with Szu-chi Huang, an expert in motivation. She explained how scie…

1
Happy New Year From The Future of Everything 1:11

8d ago1:11

1:11

Hi everyone, it’s your host, Russ. As we celebrate another holiday season and round out the year, I want to take a moment to say thank you for listening. This show started out over 8 years ago as an experiment and has not only grown to become a passion project, but also an archive of the impactful work my colleagues across Stanford dedicate their l…

1
The Year in Biotech and What’s Ahead for 2026 38:15

8d ago38:15

38:15

Biotech stocks staged a dramatic turnaround in 2025, with the XBI well outpacing the S&P 500 despite concerns over leadership changes at the U.S. Food and Drug Administration, the Trump administration’s efforts to put constraints on drug pricing, and its broader cuts to health and science agencies. A pick-up in deal-making, along with falling inter…

1
TB Throwback- Correcting the Veritasium Episode on Glyphosate 1:11:45

13d ago1:11:45

1:11:45

This is a throwback to episode 484, a very important correction of their episode on glyphosate. With so much controversy around this compound it is critical to keep the information correct and consistent with a 50 year body of evidence when discussing risk and benefit. Veritassium made some mistakes, so here they are corrected so that you can parti…

1
TB Throwback- Correcting the Veritasium Episode on Glyphosate 1:11:45

12d ago1:11:45

1:11:45

This is a throwback to episode 484, a very important correction of their episode on glyphosate. With so much controversy around this compound it is critical to keep the information correct and consistent with a 50 year body of evidence when discussing risk and benefit. Veritassium made some mistakes, so here they are corrected so that you can parti…

1
Best of: The future of AI coaching 30:55

13d ago30:55

30:55

We hope you’re enjoying the holiday season with family, friends, and loved ones. We’ll be releasing new episodes again in the new year – in the meantime, today, we’re re-running a fascinating episode on The future of AI coaching. The past few years have seen an incredible boom in AI and one of our colleagues, James Landay, a professor in Computer S…

1
Developing an Alternative to Opioids for Post-Surgical Pain 25:47

13d ago25:47

25:47

The approach to post-surgical pain relief has relied on short-duration treatments and notably opioids. That’s led to the associated risks of dependence and abuse, prolonged hospitalizations, and slower recoveries. Allay Therapeutics is developing an alternative to opioids to treat post-surgical pain with an initial focus on knee replacement surgeri…

1
TB Throwback: Gliblastoma and Cindy's Gift 1:04:24

17d ago1:04:24

1:04:24

This episode originally aired on December 18, 2021. Cindy Graham was diagnosed with glioblastoma in her late 40s. She fought the disease, and ultimately donated her tissues to research to study the nature of glioblastoma and identify potential vulnerabilities that could underlie a cure. This episode first features Dr. Shiela Singh, glioblastoma exp…

1
TB Throwback: Gliblastoma and Cindy's Gift 1:04:24

20d ago1:04:24

1:04:24

This episode originally aired on December 18, 2021. Cindy Graham was diagnosed with glioblastoma in her late 40s. She fought the disease, and ultimately donated her tissues to research to study the nature of glioblastoma and identify potential vulnerabilities that could underlie a cure. This episode first features Dr. Shiela Singh, glioblastoma exp…

1
The future of lipids in evolution 32:30

20d ago32:30

32:30

Microbes are awesome, says biologist Paula Welander. They have shaped Earth’s chemistry and its environment over billions of years, including oxygenating the planet to make it habitable for larger life forms. In turn, microbes have been shaped by that very same environment, evolving as the climate has evolved, she says. Welander now studies the lip…

1
Leveraging the Power of Vocal Biomarkers 22:19

20d ago22:19

22:19

Physicians can learn a lot from talking to patients, and not just from the words they say, but from millions of data points from acoustic features of their speech, such as pitch, vocal cord vibration patterns, and micro-instabilities in the voice. Canary Speech has developed an AI-based diagnostic listening tool that can detect neurological and psy…

1
Breathing New Life into Toxicology: Human-Relevant Models in Action 25:58

23d ago25:58

25:58

What if we could predict how chemicals affect human lungs without using animals? In this episode of Sounds of Science, Mary McElroy, Head of Discovery Toxicology and Pharmacology at Charles River, joins us to explore a groundbreaking collaboration with MatTek Life Sciences. Together, they’re pioneering human-relevant, non-animal models that could r…

1
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease 1:07:34

22d ago1:07:34

1:07:34

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).By Timmerman Report

1
TB Throwback: Dr. Avindra Nath and HERV-based Diseases 50:36

24d ago50:36

50:36

In today's throwback to 2022, Dr. Avindra Nath of the NIH reviews research efforts in proteins expressed from human endogenous retroviruses. It is a fascinating discussion of how genome relics may be contributing to insidious human disease.By Colabra

1
TB Throwback: Dr. Avindra Nath and HERV-based Diseases 50:36

24d ago50:36

50:36

In today's throwback to 2022, Dr. Avindra Nath of the NIH reviews research efforts in proteins expressed from human endogenous retroviruses. It is a fascinating discussion of how genome relics may be contributing to insidious human disease.By Colabra

1
The future of neurodegeneration 34:41

27d ago34:41

34:41

Molecular biologist Judith Frydman studies the nuances of protein folding and how defects in the process lead to neurodegenerative diseases. Her team studies protein folding in human cells and in model organisms, like yeast and worms, to understand the molecular events that precipitate harmful protein defects in humans. In one example, Frydman’s te…

1
Determining the Cause and Severity of Sepsis with a Point-of-Care Test 37:09

27d ago37:09

37:09

Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is controlled. It accounts for an estimated $53 billion in Medicare spending alone, yet more than a hundred drug trials have failed to yield a single approved drug that directl…

1
482 Dr. Maxine Thompson, Episode 117, Jan 18, 2015 37:40

1M ago37:40

37:40

This throwback episode to 2018 is an interview with plant breeding pioneer Dr. Maxine Thompson.By Colabra

1
482 Dr. Maxine Thompson, Episode 117, Jan 18, 2015 37:40

1M ago37:40

37:40

This throwback episode to 2018 is an interview with plant breeding pioneer Dr. Maxine Thompson.By Colabra

1
The future of ribosomes 34:40

1M ago34:40

34:40

Maria Barna is an authority on ribosomes – “life’s most ancient and spectacular molecular machines.” Ribosomes make proteins in the body. There can be a thousand different types of ribosomes in a single cell, she says, each with a specific job to do. But sometimes things go awry and ribosomes get “hijacked,” leading to disease. Barna studies these …

1
Separating Signal from Noise in Regenerative Therapies 32:21

1M ago32:21

32:21

Rion is developing platelet-derived exosome therapeutics as off-the-shelf, room-temperature-stable alternatives to traditional cell therapies. The company’s lead program is advancing toward phase 3 trials in diabetic foot ulcers, and it is building a broader pipeline across musculoskeletal, cardiovascular, pulmonary, dermatologic, and women’s healt…

1
Fighting For Liam - The Leston's Story 36:51

1M ago36:51

36:51

For this episode I am joined by Megan and JC Leston, two parents who are fighting for their son Liam. The oldest of their five children, Liam was born with the rare Cri du Chat or 5p- syndrome. Through years of perseverance, they have created the Cri du Chat Research Foundation and started a movement to find a cure not only for Liam, but for all fa…

1
Best of: How to take waste out of wastewater 29:19

1M ago29:19

29:19

In October, chemical engineer Will Tarpeh was awarded a 2025 MacArthur “Genius Grant” in recognition of his pioneering work to turn wastewater into a source of valuable materials. Will envisions a future in which the concept of wastewater is obsolete, thanks to advances in recycling. A couple of years ago, we sat down to talk with him about this wo…

1
Rewriting Drug Discovery with an AI-Multi-Omics Approach 45:49

1M ago45:49

45:49

The genomics revolution promised to unravel diseases and lead to treatments that addressed their root causes. In reality, says Mo Jain, your zip code remains a better predictor for how healthy you will be over the course of your life than your genetic code does. That’s because, except for monogenic diseases, etiology tends to be far more complex th…

1
The future of digital markets 31:32

2M ago31:32

31:32

Gabriel Weintraub studies how digital markets evolve. In that regard, he says platforms like Amazon, Uber, and Airbnb have already disrupted multiple verticals through their use of data and digital technologies. Now, they face both the opportunity and the challenge of leveraging AI to further transform markets, while doing so in a responsible and a…

1
Ep190: Neil Kumar on Building a Rare Disease Drug Company 1:13:12

2M ago1:13:12

1:13:12

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.By Timmerman Report

1
Overcoming Chemoresistance and Activating the Immune System in Difficult-to-Treat Cancers 36:24

2M ago36:24

36:24

The enzyme GSK3β, in healthy cells, is involved in glucose metabolism. In cancer cells, though, it serves as a master regulator of tumor growth, progression, and cell survival. While GSK3β has long been an attractive target in cancer therapy, it has been difficult to inhibit due to the poor pharmaceutical characteristics and adverse effects of ther…

1
Choosing Wisely: The Ethics, Science, and Emotion Behind Species Selection 27:45

2M ago27:45

27:45

What if one decision could make or break your drug’s success? Join Charles River’s Sarah Gould as she unpacks the high-stakes, emotion-filled world of species selection—and why it’s about so much more than science. Discover how this critical choice shapes safety, speeds development, and drives innovation in today’s evolving research landscape. Show…

1
The future of immunotherapy 33:52

2M ago33:52

33:52

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system’s “danger signals” and are …

1
Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI 1:12:33

2M ago1:12:33

1:12:33

Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.By Timmerman Report

1
A Hub-and-Spoke Ophthalmology Company with an Eye for Innovation 21:26

2M ago21:26

21:26

Hub-and-spoke business models—the use of a central core of business functions with pipeline assets spun out into subsidiary companies—have gained traction for the benefits they can provide in terms of capital efficiency, diversification of risks, and improved access to capital. Eyexora is applying that business model to accelerate the development o…

1
The future of emerging technologies 31:46

2M ago31:46

31:46

On our 300th episode, Stanford Hoover Institution Director and former U.S. Secretary of State Condoleezza Rice talks about her return to Stanford after years in government and the impact she sees rapidly advancing technologies having on democracy and public policy. She says the future demands greater collaboration among industry, academia, and gove…

1
The countdown to our 300th episode 0:25

2M ago0:25

0:25

Tune in on Friday, November 7th to listen to our 300th episode with a very special guest. Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.ads…

1
An AI Collaborative that Welcomes All into the Fold 55:46

2M ago55:46

55:46

OpenFold, an open-source, collaborative initiative founded in 2022 to address the challenges of protein structure prediction and design using artificial intelligence, emerged as a response to the restricted commercial access to DeepMind’s AlphaFold platform. Leveraging public datasets and using a pre-competitive consortium model, OpenFold seeks to …

1
Supporting Mental Health for Veterans and First Responders: A Sabbatical Story 37:31

2M ago37:31

37:31

Charles River scientist Nicole Hoekstra, herself a US Navy veteran, used her employer-supported sabbatical to help out local Oklahoma based nonprofit Inner Circle Mental Health, which focuses on aiding veterans and first responders who are struggling with their mental health. I am joined by Nicole and ICMH founder Kate Cooper to discuss what this s…

1
A Biotech Probiotic to Enhance Fiber - Dr. Zack Abbott 35:42

2M ago35:42

35:42

In this episode of the Talking Biotech podcast, Dr. Kevin Folta and Dr. Zack Abbott discuss the critical role of dietary fiber in human health, the alarming statistics regarding fiber deficiency in the population, and the innovative solutions being developed by Zbiotics to address this issue. They delve into the science behind genetically engineere…

1
A Biotech Probiotic to Enhance Fiber - Dr. Zack Abbott 35:42

2M ago35:42

35:42

In this episode of the Talking Biotech podcast, Dr. Kevin Folta and Dr. Zack Abbott discuss the critical role of dietary fiber in human health, the alarming statistics regarding fiber deficiency in the population, and the innovative solutions being developed by Zbiotics to address this issue. They delve into the science behind genetically engineere…

1
Best of: The future of transparent tissue 29:02

2M ago29:02

29:02

About a year ago, a research team at Stanford Engineering led by Guosong Hong published a paper about their work to use a common food dye to make mouse skin transparent. Their findings made a big splash and have the potential to provide a range of benefits in health care. You can imagine that if we have the ability to see what’s going on under the …

1
Hitting the Reset Button on Cellular Aging 42:46

2M ago42:46

42:46

Transcription factors control the genetic programs that maintain cellular balance, but while they have been seen as compelling targets for aging-related disease, they have long been considered “undruggable.” Junevity’s RESET platform leverages large-scale human omics data and AI models to pinpoint key transcriptional drivers of disease and to desig…

1
Ep188: Art Krieg on Innate Immune System Activators for Cancer 1:09:05

2M ago1:09:05

1:09:05

Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.By Timmerman Report

1
The future of wound healing 33:50

3M ago33:50

33:50

Clinician-scientist Jill Helms is an expert on healing. Until about age 30, people heal easily, she says, but later on, not so well. Regenerative medicine suggests avenues for improvement, she promises. Her research focuses on understanding the physical and molecular processes of healing to design better therapies. One approach awakens “sleeper” st…

1
Changing the Ovarian Cancer Treatment Landscape with a DNA-Mediated Immunotherapy 29:58

3M ago29:58

29:58

Ovarian cancer remains one of the deadliest cancers affecting women, and it is expected to claim nearly 13,000 lives in the United States in 2025. Despite progress in survival rates, nearly 80 percent of patients are still diagnosed at advanced stages, when the disease has already spread and is difficult to treat. Imunon’s experimental DNA-mediated…

1
Little Monsters: How Microbes Manage At The Edge of Existence 16:25

3M ago16:25

16:25

Ryan Cox from Microbial Solutions joins us to discuss the curious creatures living at the edges of life – from microbes pulled from the MIR space station to antibiotic resistant bacteria festering in shark mouths. Meet these and many more on this episode!By Charles River

1
Peer Review and Rigor in Controversial Science - Cam English, Dr. Liza Lockwood 55:21

3M ago55:21

55:21

This cross-platform podcast is shared on Science Facts and Fallacies as well as Talking Biotech. Cameron English, Dr. Liza Lockwood and Dr. Kevin Folta discuss the comments made during a rant on the Science Facts and Fallacies podcast concerning the rigor of peer review and alledged lack of self policing in academic publishing. They discuss several…

1
Peer Review and Rigor in Controversial Science - Cam English, Dr. Liza Lockwood 55:21

3M ago55:21

55:21

This cross-platform podcast is shared on Science Facts and Fallacies as well as Talking Biotech. Cameron English, Dr. Liza Lockwood and Dr. Kevin Folta discuss the comments made during a rant on the Science Facts and Fallacies podcast concerning the rigor of peer review and alledged lack of self policing in academic publishing. They discuss several…

1
The future of topical vaccines 37:39

3M ago37:39

37:39

Bioengineer Michael Fischbach studies alternative vaccine delivery methods, like self-administered creams with no needles, health professionals, or side effects. He teases a day when vaccines that don’t make you feel bad come in the mail in ketchup-style packets. Such innovations would greatly improve vaccine uptake, especially in developing countr…

1
Why the United States Must Fall in Love with Biotechnology, or Take a Back Seat to China 32:39

3M ago32:39

32:39

China’s emergence as a biotech superpower may have appeared to happen suddenly, but it reflected a long-term vision and policies over many years that enabled its success. As biotechnology transforms not only medicine but also industries such as food, fuel, and materials, the competition between China and the United States to shape the future bioeco…